Top

World Journal of Urology

Published in:

01-06-2009 | Topic Paper

Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)

Authors: Richard E. Hautmann, Bjoern G. Volkmer, Kilian Gust

Published in: World Journal of Urology | Issue 3/2009

Abstract

Objectives

To review understaging and survival of patients who underwent early versus deferred radical cystectomy (RCX) for high-risk non-muscle invasive bladder cancer (NMIBC; T1 G3).

Methods

The results of 1,521 RCXs including 1,420 for bladder cancer were reviewed: (1) A total of 114 patients with high-risk NMIBC underwent a single TUR-BT followed by immediate RCX to estimate the understaging rate. (2) As much as 260 patients with NMIBC had long-term follow-up before RCX to determine the upgrading and upstaging over time. (3) We compared survival in patients with initial T1 G3 bladder cancer (BC) treated with early RCX (n = 175) versus deferred RCX (n = 99) for recurrent T1 G3.

Results

(1) Our understaging rate was 20.2%. (2) Allowing NMIBC to upgrade portents a 19% survival disadvantage. (3) The 10 years cancer-specific survival rate was 78.7% in early and 64.5% in deferred RCX.

Conclusions

Early, as compared to deferred RCX, has a distinct survival advantage for high-risk NMIBC. Patients should be counselled accordingly.

Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S (2007) The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100:33–36. doi:10.1111/j.1464-410X.2007.06912.x PubMedCrossRef

Malavaud B (2004) T1 G3 bladder tumours: the case for radical cystectomy. Eur Urol 45:406–410. doi:10.1016/j.eururo.2003.11.007 PubMedCrossRef

Evans CP, Busby JE (2003) The management of stage T1 grade 3 transitional cell carcinoma of the bladder. BJU Int 92:345–348. doi:10.1046/j.1464-410X.2003.04357.x PubMedCrossRef

Stein JP, Penson DF (2008) Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 102:270–275. doi:10.1111/j.1464-410X.2008.07743.x PubMedCrossRef

Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M (2008) Early versus deferred cystectomy for initial high-risk pT1 G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152. doi:10.1016/j.eururo.2007.06.030 PubMedCrossRef

Andius P, Johansson SL, Holmäng S (2007) Prognostic factors in stage T1 bladder cancer: tumor pattern (solid of papillary) and vascular invasion more important than depth of invasion. Urology 70:758–762. doi:10.1016/j.urology.2007.06.638 PubMedCrossRef

Kamat AM, Gee JR, Dinney CPN, Grossmann HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL (2006) The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175:881–885. doi:10.1016/S0022-5347(05)00423-4 PubMedCrossRef

Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 49:466–477. doi:10.1016/j.eururo.2005.12.031 PubMedCrossRef

Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes JA (1998) Microstaging of pT1 transitional call carcinoma of the bladder: indentification of subgroups with distinct risks of progression. Urology 52:1009–1014. doi:10.1016/S0090-4295(98)00374-4 PubMedCrossRef

10.

Herr HW, Donat SM (2006) A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 97:1194–1198. doi:10.1111/j.1464-410X.2006.06145.x PubMedCrossRef

11.

Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE (2004) Primary T1 G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70–75. doi:10.1097/01.ju.0000132129.87598.3b PubMedCrossRef

12.

Schrier BP, Hollander MP, van Rhijn BWG, Kiemeney LA, Witjes JA (2004) Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45:292–296. doi:10.1016/j.eururo.2003.10.006 PubMedCrossRef

13.

Jakse G, Algaba F, Malmström PU, Oosterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45:539–546. doi:10.1016/j.eururo.2003.12.016 PubMedCrossRef

14.

Serretta V, Ruggirello A, Dispensa N, Allegro R, Darvinio Melloni FA (2008) Multiplicity and history have a detrimental effect on survival of patients with T1 G3 bladder tumors selected for conservative treatment. J Urol 180:886–891. doi:10.1016/j.juro.2008.05.013 PubMedCrossRef

15.

Konety BR (2006) Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 24:326–337. doi:10.1016/j.urolonc.2005.11.023 PubMed

16.

Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS (2001) Clinical understaging of high-risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166:490–493. doi:10.1016/S0022-5347(05)65969-1 PubMedCrossRef

17.

Fahmy NM, Mahmud S, Aprikian AG (2006) Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol 50:1176–1182. doi:10.1016/j.eururo.2006.05.046 PubMedCrossRef

18.

Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr (2003) Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 170:1085–1087. doi:10.1097/01.ju.0000086828.26001.ca PubMedCrossRef

19.

Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169:96–100. doi:10.1016/S0022-5347(05)64044-X PubMedCrossRef

20.

Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G (2007) Treatment paradigm shift may improve survival of patients with high-risk superficial bladder cancer. J Urol 177:1283–1286. doi:10.1016/j.juro.2006.11.090 PubMedCrossRef

21.

Wiesner C, Pfitzenmaier J, Faldum A, Gillitzer R, Melchior SW, Thüroff JW (2005) Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 95:301–305. doi:10.1111/j.1464-410X.2005.05287.x PubMedCrossRef

Title: Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)
Authors: Richard E. Hautmann
Bjoern G. Volkmer
Kilian Gust
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2009
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0402-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)

Abstract

Objectives

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2009

Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

Economic aspects of bladder cancer: what are the benefits and costs?

The present and future burden of urinary bladder cancer in the world

Topic issue on new treatments in bladder cancer

Bladder cancer: new TUR techniques

IL-10 −1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort